Restart Life Sciences achieved a 34.2% revenue increase in April 2026 compared to April 2025, reaching $106,288 following its acquisition of Holy Crap Foods in February 2026. The growth was driven by strong wholesale performance across over 800 Canadian retail locations and a significant boost in e-commerce sales, especially on Amazon, where revenue rose 145.7% from April 2024. The company continues to focus on optimizing distribution channels and expanding its presence in Canada, with plans to enter the U.S. and other international markets. Management views this milestone as validation of their strategy centered on gut health and functional nutrition.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
SpaceX's upcoming IPO may cause forced ETF buying of $22-$27 billion as Nasdaq changes rules to fast-track the company's index inclusion. The Nasdaq 100 now allows new companies to join within 15 days if their market cap ranks in the top 40, removing...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
A chemical incident at Melrose Industries' GKN Aerospace facility in Garden Grove, California, caused a 34,000-gallon tank of flammable methyl methacrylate to overheat, triggering evacuation orders for up to 50,000 residents. Emergency crews warned o...
